VITRIFICATION OF GENETICALLY-ENGINEERED ISLETS

Information

  • Research Project
  • 6404674
  • ApplicationId
    6404674
  • Core Project Number
    R43DK060280
  • Full Project Number
    1R43DK060280-01
  • Serial Number
    60280
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/2001 - 23 years ago
  • Project End Date
    3/31/2003 - 21 years ago
  • Program Officer Name
    EGGERMAN, THOMAS L.
  • Budget Start Date
    9/30/2001 - 23 years ago
  • Budget End Date
    3/31/2003 - 21 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/27/2001 - 23 years ago

VITRIFICATION OF GENETICALLY-ENGINEERED ISLETS

Transplantation of pancreatic islets for the treatment of diabetes mellitus is widely anticipated to eventually provide a cure once a means for preventing rejection is found without reliance upon global immunosuppression. Long-term storage of islets is crucial for the organization of transplantation, islet banking, tissue matching, organ sharing, immuno-manipulation and multiple donor transplantation. Existing methods of cryopreservation involving freezing are known to be suboptimal providing only about 50% survival. The development of techniques for ice-free cryopreservation of mammalian tissues using both natural and synthetic ice blocking molecules, and the process of vitrification (formation of a glass as opposed to crystalline ice) has been a focus of research for Organ Recovery Systems during recent years. These approaches have established in other tissues that vitrification can markedly improve survival by circumventing ice-induced injury. The aim of this Phase I study is to apply these new technologies to the long- term storage of pancreatic islets. The study is designed to optimize both the pre-vitrification hypothermic shipping conditions using newly developed media and to compare new proprietary techniques for ice- free cryopreservation with conventional freezing protocols. Optimized techniques will then be applied to genetically-modified islets designed to overcome immune responses in the diabetic host in Phase II. PROPOSED COMMERCIAL APPLICATIONS: The ultimate aim of this project is to develop a marketable package comprising cryopreserved genetically-modified islets that can be removed from vitrified storage, rewarmed simply without specialist training or equipment, and transplanted to produce a well tolerated graft with biological effectiveness that exceeds that of insulin injection therapy.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    111280
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:111280\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ORGAN RECOVERY SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CHARLESTON
  • Organization State
    SC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    294035000
  • Organization District
    UNITED STATES